Lupin Brexpiprazole tablets bags USFDA okay

Published On 2021-10-07 08:55 GMT   |   Update On 2021-10-07 08:55 GMT

Mumbai: Global pharma major Lupin Limited has recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg.The product is a generic equivalent of Rexulti Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of...

Login or Register to read the full article

Mumbai: Global pharma major Lupin Limited has recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg.

The product is a generic equivalent of Rexulti Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical Co., Ltd.

Brexpiprazole is used in the treatment of schizophrenia and as an adjunct for major depressive disorder.

This product will be manufactured at Lupin's Pithampur facility in India.

Brexpiprazole Tablets (RLD: Rexulti Tablets) had estimated annual sales of USD 1258 million in the U.S. (IQVIA MAT July 2021).
Headquartered in Mumbai, India, Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.





Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News